Abstracts Archive - Page 2129 of 2607 - ACR Meeting Abstracts

Abstract Number: 1567 • 2014 ACR/ARHP Annual Meeting
The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease
Sergio Schwartzman¹, Anton Kolomeyer² and David Chu³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Ophthalmology, University of Pittsburgh, Pittsburgh, PA, ³Ophthalmology, Rutgers, Newark, NJ
Background/Purpose: Psoriatic disease is characterized by the presence of psoriasis with or without an association of extra-dermal manifestations. Inflammatory forms of arthritis are the most…
Abstract Number: 1566 • 2014 ACR/ARHP Annual Meeting
The Efficacy and Safety of Biological Disease Modifying Anti-Rheumatic Drugs and Apremilast in the Treatment of Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Arthur N. Lau¹, Michael Zoratti², Alfred Cividino³, William Bensen³, Jonathan D. Adachi³ and Christopher Edwards⁴, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Clinical Epidemiology and Biostatistics, Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Background/Purpose Currently, there are a number of effective therapies for psoriatic arthritis (PsA). The objective of this systematic review was to assess the efficacy (PSARC,…
Abstract Number: 1565 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Vibeke Strand², Arthur Kavanaugh³, Philip J. Mease⁴, Christopher J. Edwards⁵, Maurizio Cutolo⁶, Frédéric Lioté⁷, Paul Bird⁸, Randall M. Stevens⁹, Lichen Teng⁹, Marla Hochfeld⁹ and Georg A. Schett¹⁰, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Stanford University, Portola Valley, CA, ³University of California San Diego, La Jolla, CA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University Hospital Southampton, Southampton, United Kingdom, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁷Rheumatology Department, University Paris Diderot, Paris, France, ⁸Combined Rheumatology Practice, Kogarah, Australia, ⁹Celgene Corporation, Warren, NJ, ¹⁰Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 1564 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension
Philip J. Mease¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephan Hall⁵, Arthur Kavanaugh⁶, Eric Lespessailles⁷, Georg A. Schett⁸, Kamal Shah⁹, Randall M. Stevens⁹, Lichen Teng⁹ and Jürgen Wollenhaupt¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Sheffield, Sheffield, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁵Cabrini Health and Monash University, Melbourne, Australia, ⁶University of California San Diego, La Jolla, CA, ⁷University of Orléans, Orléans, France, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), a phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE 1,…
Abstract Number: 1582 • 2014 ACR/ARHP Annual Meeting
Cumulative Inflammatory Burden Is Independently Associated with Increased Arterial Stiffness in Patients with Psoriatic Arthritis
Jiayun Shen¹, Qing Shang¹, Ying Ying Leung², Edmund Li¹, Tracy Y. Zhu¹ and Lai-Shan Tam¹, ¹Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk of cardiovascular (CV) morbidity compared with the general population, probably as a result of chronic…
Abstract Number: 1580 • 2014 ACR/ARHP Annual Meeting
Gender Differences in Disease Activity Accounting for Inflammatory Biomarkers in a Psoriatic Arthritis Routine Care Cohort
Soumya M. Reddy¹, Jose U. Scher¹, Christopher Swearingen² and Yusuf Yazici¹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose: Routine care cohorts can provide data about patient phenotypes, treatment choices and responses in the 'real world'. Studying the true impact of psoriatic arthritis…
Abstract Number: 1581 • 2014 ACR/ARHP Annual Meeting
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies
Majed Khraishi¹, Heather Jones^2,3 and Annette Szumski⁴, ¹Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, St. John's, NF, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) may have clinical features suggestive of axial skeletal abnormalities and should be assessed for the presence…
Abstract Number: 1579 • 2014 ACR/ARHP Annual Meeting
Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Dafna D. Gladman², Arthur Kavanaugh³, Adewale O. Adebajo⁴, Juan Gomez-Reino⁵, Jurgen Wollenhaupt⁶, Georg A. Schett⁷, Kamal Shah⁸, ChiaChi Hu⁸, Randall M. Stevens⁸, Christopher Edwards⁹ and Charles A. Birbara¹⁰, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of California San Diego, La Jolla, CA, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Schön-Klinik, Hamburg, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Warren, NJ, ⁹Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁰University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is a PDE4 inhibitor that helps regulate the immune response. PALACE 1, 2, and 3 assessed the efficacy and safety of APR…
Abstract Number: 1574 • 2014 ACR/ARHP Annual Meeting
University Students with Psoriatic Nail Changes Have a Greater Number of Tender Enthesial Points Than Those with Normal Nails
A Eftal Yucel¹, Melih Pamukcu², Elif Durukan³, Busra Tosun⁴, Berk Batman⁴, Omer Ozkan⁴ and Anil Kocak⁴, ¹Int Medicine Rheumatology, Baskent University Faculty of Medicine, Ankara, Turkey, ²Internal Medicine Rheumatology, Baskent University Faculty of Medicine, Ankara, Turkey, ³Public Health, Baskent University Faculty of Medicine, Ankara, Turkey, ⁴Baskent University Faculty of Medicine, Ankara, Turkey
Background/Purpose Nail pitting is present in about 10% of healthy adults, and more than 50% of patients with psoriatic arthritis. We believe that the prevalence…
Abstract Number: 1545 • 2014 ACR/ARHP Annual Meeting
Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab
Philip J. Mease¹, Filip van Den Bosch², Joachim Sieper³, Aileen L. Pangan⁴, Nupun A. Varothai⁴ and In-Ho Song⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Ghent University Hospital, Ghent, Belgium, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) is characterized by arthritis, enthesitis, and/or dactylitis. Enthesitis is considered a core outcome domain for SpA; however, there is no clear…
Abstract Number: 1544 • 2014 ACR/ARHP Annual Meeting
Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis
Steven R Feldman¹, Yang Zhao², Lizheng Shi³, Jackie Lu² and MaryHelen Tran², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Tulane University, New Orleans, LA
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with substantial economic and comorbidity burdens. However, the burden among PsO patients comorbid with PsA has…
Abstract Number: 1543 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
Alvin Wells¹, Adewale O. Adebajo², Jacob A. Aelion³, Paul Bird⁴, Alan Kivitz⁵, Frédéric Lioté⁶, Piercarlo Sarzi-Puttini⁷, ChiaChi Hu⁸, Randall M. Stevens⁸ and Christopher J. Edwards⁹, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University of Sheffield, Sheffield, United Kingdom, ³West Tennessee Research Institute, Jackson, TN, ⁴Combined Rheumatology Practice, Kogarah, Australia, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁷Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁸Celgene Corporation, Warren, NJ, ⁹University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE…
Abstract Number: 1555 • 2014 ACR/ARHP Annual Meeting
An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate (MTX) and Apremilast in the Treatment of MTX-naïve Psoriatic Arthritis (PsA) Patients
Vibeke Strand¹, Jenny Griffith², Keith Betts³, Alan Friedman², James Signorovitch³ and Arijit Ganguli^2,4, ¹Stanford University, Palo Alto, CA, ²AbbVie, Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Apremilast (APR), a small molecule inhibitor of phospodiesterase 4 (PDE-4), was recently approved for treating PsA patients in the US. To date, there are…
Abstract Number: 1554 • 2014 ACR/ARHP Annual Meeting
Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies
Iain B. McInnes¹, Christopher T. Ritchlin², Proton Rahman³, Lluís Puig Sanz⁴, Alice B. Gottlieb⁵, Shu Li⁶, Michael Song⁶, Bruce Randazzo⁶, Yuhua Wang⁶, Alan M. Mendelsohn⁷ and Arthur Kavanaugh⁸, ¹University of Glasgow, Glasgow, United Kingdom, ²Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Tufts Medical Center, Boston, MA, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁸University of California San Diego, La Jolla, CA
Background/Purpose: We have previously reported the efficacy and safety results of ustekinumab (UST), an IL-12/23 p40 inhibitor, in patients with active psoriatic arthritis (PsA) up…
Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Philip J. Mease¹, Roy Fleischmann², Owen Davies³, Tommi Nurminen⁴ and Désirée van der Heijde⁵, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].